These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 3856974)

  • 21. Effectiveness of perioperative prophylaxis with ceftriaxone and cefotaxime in vaginal hysterectomy with and without anterior and/or posterior colporrhaphy.
    Harms E; Schumacher C
    Chemioterapia; 1987 Jun; 6(2 Suppl):622-3. PubMed ID: 3334650
    [No Abstract]   [Full Text] [Related]  

  • 22. Bacteriological comparison of the activities of ceftriaxone, a new long-acting cephalosporin, with those of other new cephalosporins.
    Arisawa M; Ohshima J; Ohsawa E; Maruyama HB; Sekine Y; Mitsuhashi S
    Chem Pharm Bull (Tokyo); 1982 Jul; 30(7):2544-54. PubMed ID: 6291792
    [No Abstract]   [Full Text] [Related]  

  • 23. [In vitro bacteriostatic activity of cefmenoxime (SCE 1365), cefotaxime and moxalactam].
    Husson MO; Bryskier A; Izard D; Leclerc H
    Pathol Biol (Paris); 1983 May; 31(5):347-50. PubMed ID: 6312395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Ceftriaxone in pediatric surgery].
    Brülhart K; Schärli AF
    Wien Med Wochenschr Suppl; 1985; 87():28-32. PubMed ID: 3856973
    [No Abstract]   [Full Text] [Related]  

  • 25. Ceftriaxone: a long-acting cephalosporin.
    Am J Med; 1984 Oct; 77(4C):1-118. PubMed ID: 6093510
    [No Abstract]   [Full Text] [Related]  

  • 26. [Update on antibiotic therapy. 20) Ceftriaxone].
    Di Nola F
    Minerva Med; 1984 Jan; 75(3-4):137-41. PubMed ID: 6322055
    [No Abstract]   [Full Text] [Related]  

  • 27. [In vitro antibacterial activity of cefmenoxime (SCE 1365)].
    Brun Y; Forey F; Coulet M; Fleurette J; Bryskier A
    Pathol Biol (Paris); 1983 May; 31(5):343-6. PubMed ID: 6312394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative activity of ceftizoxime and four other cephalosporins against gram negative bacteria and their sensitivity to beta-lactamases.
    Esposito S; Galante D; Barba D; Pennucci C; Limauro D
    Microbiologica; 1985 Apr; 8(2):197-204. PubMed ID: 3874342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences between ceftriaxone and cefotaxime: microbiological inconsistencies.
    Gums JG; Boatwright DW; Camblin M; Halstead DC; Jones ME; Sanderson R
    Ann Pharmacother; 2008 Jan; 42(1):71-9. PubMed ID: 18094350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Evaluation of ceftriaxone (R013-9904) in the treatment of septicemia caused by gram-negative bacilli].
    Naessens A; Pierard D; Roels P; Lauwers S
    Pathol Biol (Paris); 1983 May; 31(5):362-5. PubMed ID: 6312398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ceftriaxone therapy of meningitis and serious infections.
    Steele RW
    Am J Med; 1984 Oct; 77(4C):50-3. PubMed ID: 6093519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial activity of ceftriaxone versus cefotaxime: negative effect of serum albumin binding of ceftriaxone.
    Nath SK; Foster GA; Mandell LA; Rotstein C
    J Antimicrob Chemother; 1994 Jun; 33(6):1239-43. PubMed ID: 7928818
    [No Abstract]   [Full Text] [Related]  

  • 33. Ceftriaxone in the treatment of serious infections, particularly after surgery.
    Scully BE; Neu HC
    Am J Surg; 1984 Oct; 148(4A):35-40. PubMed ID: 6091479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of formulas for calculating critical concentration by the agar diffusion method.
    Drugeon HB; Juvin ME; Caillon J; Courtieu AL
    Antimicrob Agents Chemother; 1987 Jun; 31(6):870-5. PubMed ID: 3619419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ceftriaxone: renal and biliary excretion and effect on the colon microflora.
    Arvidsson A; Alván G; Angelin B; Borgå O; Nord CE
    J Antimicrob Chemother; 1982 Sep; 10(3):207-15. PubMed ID: 6292158
    [No Abstract]   [Full Text] [Related]  

  • 36. [The activity of a new cephalosporin (ceftriaxone) against bacteria isolated in a hospital environment].
    Bouzouaia N; Chaabane TB; Salem NB; Tiouiri H; Zribi A
    Tunis Med; 1991 Feb; 69(2):109-12. PubMed ID: 2063483
    [No Abstract]   [Full Text] [Related]  

  • 37. Interpretive criteria for antimicrobial susceptibility tests with cefodizime discs.
    Fuchs PC; Barry AL
    J Antimicrob Chemother; 1991 Jun; 27(6):870-3. PubMed ID: 1938699
    [No Abstract]   [Full Text] [Related]  

  • 38. Desacetylcefotaxime--another broad spectrum cephalosporin?
    Fuchs PC; Jones RN; Barry AL; Allen SD; Ayers LW; Pfaller M
    J Antimicrob Chemother; 1989 Jan; 23(1):165-7. PubMed ID: 2745252
    [No Abstract]   [Full Text] [Related]  

  • 39. Symposium: new findings on the antibacterial interactions between cefotaxime and desacetylcefotaxime.
    Diagn Microbiol Infect Dis; 1989; 12(1):23-121. PubMed ID: 2714069
    [No Abstract]   [Full Text] [Related]  

  • 40. Cefotaxime and desacetyl cefotaxime in human bile.
    Kees F; Strehl E; Dominiak P; Grobecker H; Seeger K; Seidel G; Neuhaus B; Safrany L
    Infection; 1983; 11(2):118-20. PubMed ID: 6305848
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.